UNIT 5.31 Emetic Liability Testing in Ferrets

  1. Mark A. Osinski,
  2. Terese R. Seifert,
  3. Thomas K. Shaughnessy,
  4. Gary A. Gintant,
  5. Bryan F. Cox

Published Online: 1 MAY 2003

DOI: 10.1002/0471141755.ph0531s20

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

Osinski, M. A., Seifert, T. R., Shaughnessy, T. K., Gintant, G. A. and Cox, B. F. 2003. Emetic Liability Testing in Ferrets. Current Protocols in Pharmacology. 20:5.31:5.31.1–5.31.8.

Author Information

  1. Abbott Laboratories, Abbott Park, Illinois

Publication History

  1. Published Online: 1 MAY 2003
  2. Published Print: MAR 2003


Evidence of a candidate drug's efficacy and safety is mandatory for successful drug registration by regulatory authorities. However, a third property, tolerability, often determines a drug's acceptance by the patient population. Gastrointestinal events often determine the maximum tolerated dose in Phase I clinical trials. If the plasma concentrations achieved at the maximum tolerable dose are below those required for efficacy, the drug will certainly fail. The identification of a compound's emetic/nauseogenic liability early in the discovery process can be critical to the ultimate success of the drug discovery project. Ferrets are small carnivores (∼1 kg) of the Mustelidae family that vomit in response to many pharmacological classes of drugs as well as to cytotoxic chemotherapeutics and radiation. This unit describes a simple method for evaluating the emetic and nauseogenic potential of drug candidates in ferrets.